ema glp-1 vision loss recommendation october 2025 finds no link between receptor agonists and suicidal thoughts EMA Warns of Vision Risk

Tirzepatide is a groundbreaking compound currently being researched for its potential benefits in weight management and glycemic control

Some of those things can be caused by a GLP-1, such as weight loss or improved insulin sensitivity

Patterns only emerge over time

The real version, backed by data from the STEP clinical trials, published research on GLP-1 receptor agonists, and documented experiences from thousands of researchers who have navigated this exact timeline

Zad Z, Jiang VS, Wolf AT, Wang T, Cheng JJ, Paschalidis IC, Mahalingaiah S (2024) Predicting polycystic ovary syndrome with machine learning algorithms from electronic health records